The Alzheimer’s Association and the Rainwater Charitable Foundation have joined forces again to fund drug discovery research towards finding therapies for Alzheimer’s disease, frontotemporal degeneration, and other tauopathies. The partners are awarding nearly $4 million to fund drug discovery approaches that aim to remove or mitigate the effects of abnormal tau, a toxic brain protein that is a hallmark of Alzheimer’s disease, frontotemporal dementia, and other tauopathies. Previous studies have found that removing or blocking tau “tangles” holds great potential to delay, slow or prevent Alzheimer’s and other dementia, making it a high priority target for therapies.
Research with a sense of urgency
The Tau Consortium’s mission is to accelerate the development of new treatments for Alzheimer’s disease, frontotemporal dementias, and other neurodegenerative diseases involving the dysfunctional tau protein. We help scientists to work collaboratively, engage strategic partners who share our mission, and establish the critical resources needed to accelerate progress for understanding the underlying causes of these tau-related neurodegenerative diseases. Tau Consortium participants act with urgency and with patients in mind to develop novel approaches and cutting-edge treatments.
Since founding the Tau Consortium in 2009, the Rainwater Charitable Foundation has committed over $100 million to the program and has helped to put eight treatments into human trials.